Avoid common mistakes on your manuscript.
Correction to: Journal of Neurology https://doi.org/10.1007/s00415-023-11687-1
The original version of this article unfortunately contained a mistake. There are 2 data errors in the results section of the abstract.
In abstract, first sentence of the results section should read as
As of January 31, 2022, 307 patients were enrolled from 14 countries. Mean (standard deviation [SD]) ages at first symptoms and at genetic diagnosis were 2.9 (1.7) years and 5.4 (3.1) years, respectively. Mean (SD) duration of ataluren exposure was 1671 (566.8) days.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Mercuri, E., Osorio, A.N., Muntoni, F. et al. Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis. J Neurol 270, 4583 (2023). https://doi.org/10.1007/s00415-023-11864-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-023-11864-2